A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-2)
Lay Description
Category
- IRB Number
- 20220357HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Agustin Escalante
(210) 567-4682
escalante@uthscsa.edu
Regulatory Point of Contact
Jose Restrepo Suarez
(210) 567-4656
restreposuar@uthscsa.edu
Principal Investigator
Agustin Escalante